Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8639137 | 0.90 | GAA (0.46) | ALDH1A1PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL11825469 | 0.86 | CASP1 (0.45) | ALDH1A1PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6998444 | 0.85 | GAA (0.45) | ALDH1A1LMNAKDM4ESMN1; SMN2GAA | |
| SCHEMBL7465770 | 0.85 | GAA (0.37) | ALDH1A1CASP1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL11816778 | 0.83 | GAA (0.42) | ALDH1A1LMNAKDM4ESMN1; SMN2GAA | |
| SCHEMBL7487771 | 0.83 | KMT2A (0.37) | ALDH1A1CASP1TSHRLMNAKDM4E | |
| SCHEMBL6992040 | 0.83 | SLC6A4 (0.47) | TSHRSMN1; SMN2GAACYP2C19HTT | |
| SCHEMBL6995994 | 0.82 | GAA (0.41) | ALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL7954832 | 0.82 | OPRM1 (0.44) | ALDH1A1GAA | |
| SCHEMBL11817118 | 0.81 | GAA (0.41) | ALDH1A1CASP1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920425-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-0874843-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6423704-B2 | CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS | AVENTIS PHARMACEUTICALS INC. | 2002-07-23 | — | — | US | disclosed |
| EP-0946548-B1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES | AVENTIS PHARMA INC (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6329392-B1 | ANTIALLERGENS | AVENTIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | AVENTIS PHARMACEUTICALS INC. | 2001-10-25 | — | — | US | disclosed |
| EP-0946545-B1 | NOVEL CARBOXY SUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES | AVENTIS PHARMA INC (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6211199-B1 | HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS | AVENTIS PHARMACEUTICALS INC. | 2001-04-03 | — | — | US | disclosed |
| US-6194406-B1 | HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS | AVENTIS PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | disclosed |
| US-5977139-A | Carboxysubstituted cyclic carboxamide derivatives | HOECHST MARION ROUSSEL, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1998027085-A1 | NOVEL CARBOXY SUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998027086-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0696280-B1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL PHARMA INC (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5661160-A | ADMINISTERING AN ANTITUSSIVE AGENT FOR TREATING COUGH; TACHYKININ ANTAGONISM, SUBSTANCE P AND NEUROKININ A ANTAGONISM | MERRELL PHARMACEUTICALS INC. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5648366-A | TACHYKININ ANTAGONISTS USEFUL IN TREATING ASTHMA | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0777666-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5635510-A | TACHYKININ (ESPECIALLY SUBSTANCE P AND NEUROKININ A) ANTAGONISTS; ANTIINFLAMMATORY AGENTS, ANALGESICS; NERVOUS SYSTEM DISORDERS; BRONCHODILATOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-03 | — | — | US | disclosed |
| WO-1996006094-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0696280-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMA (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994026735-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | HRH4, HRH2, HRH1 | ALDH1A1 953/4885PDE4B 494/4885PDE4D 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.